As a result of the directed share issue which was approved at an extraordinary general meeting on 10 April, 2017, during April 2017 the number of shares and votes in XVIVO Perfusion AB (publ) has increased by 2,361,408 shares and votes. As of April 28, 2017 there are thus in total 25,975,496 shares and votes in the company.
April 28, 2017
Gothenburg
Christoffer Rosenblad, CFO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on April 28, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.